The role of COVID‐19 survivor status and gender towards neutralizing antibody titers 1, 2, 3 months after Sinovac vaccine administration on clinical‐year medical students in Indonesia
Authors:
- Rivaldo Steven HeriyantoRHRivaldo Steven Heriyanto
- Andree KurniawanAKAndree Kurniawan
- Felix WijoviFWFelix Wijovi
- Devina Adella HalimDHDevina Adella Halim
- Claudia JodhinataCJClaudia Jodhinata
- Elizabeth MarcellaEMElizabeth Marcella
- Billy SusantoBSBilly Susanto
- Johan WibowoJWJohan Wibowo
- Michele IndrawanMIMichele Indrawan
- Nadia Khoirunnisa HeryadiNHNadia Khoirunnisa Heryadi
- Michelle ImanuellyMIMichelle Imanuelly
- Jonathan Juniard AnuranthaJAJonathan Juniard Anurantha
Open Access
- 12 October 2021
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 113, 336-338
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, ItalyJAMA Internal Medicine, 2021
- Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in TurkeyThe Lancet, 2021
- SARS-CoV-2 Antibody Response in Persons with Past Natural InfectionNew England Journal of Medicine, 2021
- COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variantsNature Communications, 2021
- Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: A systematic review and meta-analysisF1000Research, 2021
- Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA VaccineNew England Journal of Medicine, 2021
- Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysisClinical and Experimental Pharmacology and Physiology, 2021
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2021
- Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan areaPLOS ONE, 2021
- A comparison study of SARS‐CoV‐2 IgG antibody between male and female COVID‐19 patients: A possible reason underlying different outcome between sexJournal of Medical Virology, 2020